echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Cinda anti-CD47/PD-L1 bispecific antibody Phase I clinical completion of China's first patient administration.

    Cinda anti-CD47/PD-L1 bispecific antibody Phase I clinical completion of China's first patient administration.

    • Last Update: 2020-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    The study (CIBI322A101) was a phase Ia/Ib clinical study conducted in China to evaluate IBI322 treatment of subjects with advanced malignancies, with the main purpose of the study being to assess the safety, tolerance and antitumor activity of IBI322 bispecific antibody therapy in subjects with advanced malignancies with standard treatment failures.
    IBI322 is an anti-CD47/PD-L1 bispecific antibody that blocks both PD-1/PD-L1 and CD47/SIRP-alpha pathways.
    preclinical studies show that IBI322 can effectively block the binding of SIRP-alpha and CD47, induce macrophages to perform a phagocytopharycal effect on tumor cells expressing CD47, the ability is comparable to anti-CD47 monoantiphoresis;
    also due to the presence of PD-L1, IBI322 selectivebinding to tumor cells is more capable than anti-CD47 monotophoid, thereby reducing the binding with CD47 on the surface of red blood cells, reducing the likelihood of associated toxicity.
    , IBI322 has better anti-tumor activity and greater safety.
    Note: The original text has a limitation.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.